Pharmaceutical

Agenus and Zydus sign agreements for botensilimab and balstilimab

Agenus has signed $141m partnership agreements with Zydus Lifesciences, expanding patient access to BOT/BAL.

Jun 5, 2025 - 06:00
Agenus and Zydus sign agreements for botensilimab and balstilimab
Agenus has signed $141m partnership agreements with Zydus Lifesciences, expanding patient access to BOT/BAL.
Read the original article

Tags:

Previous Article

Redwire gains Aspera contract for space-based cancer research

Next Article

Magazine: Are regulators keeping pace with AI adoption in clinical trials?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Aduhelm was a mess — and it could happen again

Opinion: Aduhelm was a mess — and it could happen again

Feb 7, 2024

Biden’s FDA is letting Ron DeSantis import cheaper drugs from Canada. Who gets to take credit?

Biden’s FDA is letting Ron DeSantis import cheaper drug...

Jan 6, 2024

Navigator gains $100m in Series A funding for antibody therapeutics

Navigator gains $100m in Series A funding for antibody ...

Aug 29, 2024